Which has better valuation & earnings, CO or MRAI?

Global Cord Blood has higher revenue and earnings than Marpai. Marpai is trading at a lower price-to-earnings ratio than Global Cord Blood, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Global Cord Blood $1.24B 0.09 $79.04M $0.64 1.48 Marpai $34.87M 0.42 -$28.75M -$0.87 N/A

Is CO or MRAI more profitable?

Global Cord Blood has a net margin of 0.00% compared to Marpai's net margin of -85.70%. Company Net Margins Return on Equity Return on Assets Global Cord Blood N/A N/A N/A Marpai -85.70% N/A -100.23%

Do analysts rate CO or KMDA?

Kamada has a consensus price target of $12.00, suggesting a potential upside of 67.36%. Given Kamada's stronger consensus rating and higher possible upside, analysts plainly believe Kamada is more favorable than Global Cord Blood. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Global Cord Blood 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Kamada 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has better earnings and valuation, CO or KMDA?

Global Cord Blood has higher revenue and earnings than Kamada. Global Cord Blood is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Global Cord Blood $1.24B 0.09 $79.04M $0.64 1.48 Kamada $181.68M 2.27 $20.20M $0.35 20.49

Do analysts prefer KIDS or CO?

OrthoPediatrics currently has a consensus price target of $24.44, indicating a potential upside of 33.43%. Given OrthoPediatrics' stronger consensus rating and higher probable upside, analysts clearly believe OrthoPediatrics is more favorable than Global Cord Blood. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OrthoPediatrics 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.82 Global Cord Blood 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer AUTL or CO?

Autolus Therapeutics currently has a consensus price target of $8.75, suggesting a potential upside of 471.90%. Given Autolus Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Autolus Therapeutics is more favorable than Global Cord Blood. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Autolus Therapeutics 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 2.89 Global Cord Blood 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer CO or UPB?

Upstream Bio has a consensus price target of $38.20, suggesting a potential upside of 441.84%. Given Upstream Bio's stronger consensus rating and higher probable upside, analysts clearly believe Upstream Bio is more favorable than Global Cord Blood. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Global Cord Blood 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Upstream Bio 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50

Global Cord Blood (CO) Competitors

$0.95 0.00 (0.00%)

As of 06/5/2026

Compare

CO vs. MRAI, KMDA, KIDS, AUTL, and UPB

Should you buy Global Cord Blood stock or one of its competitors? MarketBeat compares Global Cord Blood with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Global Cord Blood include Marpai (MRAI), Kamada (KMDA), OrthoPediatrics (KIDS), Autolus Therapeutics (AUTL), and Upstream Bio (UPB).

How does Global Cord Blood compare to Marpai?

Global Cord Blood (NYSE:CO) and Marpai (NASDAQ:MRAI) are both small-cap miscellaneous health & allied services, not elsewhere classified industry companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

Global Cord Blood has a net margin of 0.00% compared to Marpai's net margin of -85.70%.

Company	Net Margins	Return on Equity	Return on Assets
Global Cord Blood	N/A	N/A	N/A
Marpai	-85.70%	N/A	-100.23%

49.8% of Marpai shares are held by institutional investors. 0.5% of Global Cord Blood shares are held by company insiders. Comparatively, 46.1% of Marpai shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Global Cord Blood has higher revenue and earnings than Marpai. Marpai is trading at a lower price-to-earnings ratio than Global Cord Blood, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Global Cord Blood	$1.24B	0.09	$79.04M	$0.64	1.48
Marpai	$34.87M	0.42	-$28.75M	-$0.87	N/A

Global Cord Blood has a beta of 0.16, suggesting that its stock price is 84% less volatile than the broader market. Comparatively, Marpai has a beta of 4.94, suggesting that its stock price is 394% more volatile than the broader market.

In the previous week, Global Cord Blood's average media sentiment score of 0.00 equaled Marpai'saverage media sentiment score.

Company	Overall Sentiment
Global Cord Blood	Neutral
Marpai	Neutral

Summary

Global Cord Blood beats Marpai on 6 of the 10 factors compared between the two stocks.

How does Global Cord Blood compare to Kamada?

Global Cord Blood (NYSE:CO) and Kamada (NASDAQ:KMDA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and dividends.

In the previous week, Kamada had 4 more articles in the media than Global Cord Blood. MarketBeat recorded 4 mentions for Kamada and 0 mentions for Global Cord Blood. Kamada's average media sentiment score of 0.24 beat Global Cord Blood's score of 0.00 indicating that Kamada is being referred to more favorably in the news media.

Company	Overall Sentiment
Global Cord Blood	Neutral
Kamada	Neutral

Kamada has a consensus price target of $12.00, suggesting a potential upside of 67.36%. Given Kamada's stronger consensus rating and higher possible upside, analysts plainly believe Kamada is more favorable than Global Cord Blood.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Global Cord Blood	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Kamada	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Global Cord Blood has a beta of 0.16, meaning that its stock price is 84% less volatile than the broader market. Comparatively, Kamada has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market.

Global Cord Blood has higher revenue and earnings than Kamada. Global Cord Blood is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Global Cord Blood	$1.24B	0.09	$79.04M	$0.64	1.48
Kamada	$181.68M	2.27	$20.20M	$0.35	20.49

20.4% of Kamada shares are owned by institutional investors. 0.5% of Global Cord Blood shares are owned by insiders. Comparatively, 36.1% of Kamada shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Global Cord Blood pays an annual dividend of $0.08 per share and has a dividend yield of 8.4%. Kamada pays an annual dividend of $0.18 per share and has a dividend yield of 2.5%. Global Cord Blood pays out 12.5% of its earnings in the form of a dividend. Kamada pays out 51.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Global Cord Blood is clearly the better dividend stock, given its higher yield and lower payout ratio.

Kamada has a net margin of 11.21% compared to Global Cord Blood's net margin of 0.00%. Kamada's return on equity of 7.73% beat Global Cord Blood's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Global Cord Blood	N/A	N/A	N/A
Kamada	11.21%	7.73%	5.41%

Summary

Kamada beats Global Cord Blood on 13 of the 18 factors compared between the two stocks.

How does Global Cord Blood compare to OrthoPediatrics?

OrthoPediatrics (NASDAQ:KIDS) and Global Cord Blood (NYSE:CO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.

69.1% of OrthoPediatrics shares are owned by institutional investors. 32.7% of OrthoPediatrics shares are owned by insiders. Comparatively, 0.5% of Global Cord Blood shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Global Cord Blood has higher revenue and earnings than OrthoPediatrics. OrthoPediatrics is trading at a lower price-to-earnings ratio than Global Cord Blood, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OrthoPediatrics	$236.35M	1.99	-$39.65M	-$1.68	N/A
Global Cord Blood	$1.24B	0.09	$79.04M	$0.64	1.48

OrthoPediatrics currently has a consensus price target of $24.44, indicating a potential upside of 33.43%. Given OrthoPediatrics' stronger consensus rating and higher probable upside, analysts clearly believe OrthoPediatrics is more favorable than Global Cord Blood.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OrthoPediatrics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Global Cord Blood	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Global Cord Blood has a net margin of 0.00% compared to OrthoPediatrics' net margin of -16.31%. Global Cord Blood's return on equity of 0.00% beat OrthoPediatrics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OrthoPediatrics	-16.31%	-7.01%	-4.86%
Global Cord Blood	N/A	N/A	N/A

In the previous week, OrthoPediatrics' average media sentiment score of 0.00 equaled Global Cord Blood'saverage media sentiment score.

Company	Overall Sentiment
OrthoPediatrics	Neutral
Global Cord Blood	Neutral

OrthoPediatrics has a beta of 1.03, suggesting that its stock price is 3% more volatile than the broader market. Comparatively, Global Cord Blood has a beta of 0.16, suggesting that its stock price is 84% less volatile than the broader market.

Summary

OrthoPediatrics beats Global Cord Blood on 8 of the 15 factors compared between the two stocks.

How does Global Cord Blood compare to Autolus Therapeutics?

Autolus Therapeutics (NASDAQ:AUTL) and Global Cord Blood (NYSE:CO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, earnings, dividends, analyst recommendations, valuation and profitability.

In the previous week, Autolus Therapeutics' average media sentiment score of 1.00 beat Global Cord Blood's score of 0.00 indicating that Autolus Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Autolus Therapeutics	Positive
Global Cord Blood	Neutral

72.8% of Autolus Therapeutics shares are held by institutional investors. 25.7% of Autolus Therapeutics shares are held by insiders. Comparatively, 0.5% of Global Cord Blood shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Global Cord Blood has higher revenue and earnings than Autolus Therapeutics. Autolus Therapeutics is trading at a lower price-to-earnings ratio than Global Cord Blood, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autolus Therapeutics	$75.39M	5.40	-$287.53M	-$1.09	N/A
Global Cord Blood	$1.24B	0.09	$79.04M	$0.64	1.48

Autolus Therapeutics has a beta of 2.02, suggesting that its share price is 102% more volatile than the broader market. Comparatively, Global Cord Blood has a beta of 0.16, suggesting that its share price is 84% less volatile than the broader market.

Autolus Therapeutics currently has a consensus price target of $8.75, suggesting a potential upside of 471.90%. Given Autolus Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Autolus Therapeutics is more favorable than Global Cord Blood.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Global Cord Blood	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Global Cord Blood has a net margin of 0.00% compared to Autolus Therapeutics' net margin of -311.98%. Global Cord Blood's return on equity of 0.00% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Autolus Therapeutics	-311.98%	-128.59%	-46.25%
Global Cord Blood	N/A	N/A	N/A

Summary

Autolus Therapeutics beats Global Cord Blood on 9 of the 16 factors compared between the two stocks.

How does Global Cord Blood compare to Upstream Bio?

Global Cord Blood (NYSE:CO) and Upstream Bio (NASDAQ:UPB) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation and institutional ownership.

Global Cord Blood has higher revenue and earnings than Upstream Bio. Upstream Bio is trading at a lower price-to-earnings ratio than Global Cord Blood, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Global Cord Blood	$1.24B	0.09	$79.04M	$0.64	1.48
Upstream Bio	$3.32M	115.49	-$143.44M	-$2.91	N/A

Global Cord Blood has a net margin of 0.00% compared to Upstream Bio's net margin of -4,718.96%. Global Cord Blood's return on equity of 0.00% beat Upstream Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Global Cord Blood	N/A	N/A	N/A
Upstream Bio	-4,718.96%	-43.82%	-42.27%

Upstream Bio has a consensus price target of $38.20, suggesting a potential upside of 441.84%. Given Upstream Bio's stronger consensus rating and higher probable upside, analysts clearly believe Upstream Bio is more favorable than Global Cord Blood.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Global Cord Blood	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Upstream Bio	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Global Cord Blood has a beta of 0.16, indicating that its share price is 84% less volatile than the broader market. Comparatively, Upstream Bio has a beta of 1.1, indicating that its share price is 10% more volatile than the broader market.

In the previous week, Upstream Bio had 10 more articles in the media than Global Cord Blood. MarketBeat recorded 10 mentions for Upstream Bio and 0 mentions for Global Cord Blood. Upstream Bio's average media sentiment score of 1.17 beat Global Cord Blood's score of 0.00 indicating that Upstream Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Global Cord Blood	Neutral
Upstream Bio	Positive

Summary

Global Cord Blood and Upstream Bio tied by winning 7 of the 14 factors compared between the two stocks.

Get Global Cord Blood News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CO vs. The Competition

Export

Metric	Global Cord Blood	health & allied services, not elsewhere classified Industry	Medical Sector	NYSE Exchange
Market Cap	$115.47M	$81.84M	$6.46B	$23.35B
Dividend Yield	N/A	N/A	2.68%	4.08%
P/E Ratio	1.48	0.74	23.82	30.26
Price / Sales	0.09	0.26	577.54	13.22
Price / Cash	4.19	4.19	42.42	24.41
Price / Book	0.15	0.15	9.73	4.63
Net Income	$79.04M	$25.15M	$3.57B	$1.07B
7 Day Performance	N/A	-7.93%	-1.26%	-1.66%
1 Month Performance	-0.05%	37.00%	0.82%	-1.68%
1 Year Performance	N/A	-27.64%	24.09%	21.33%

Global Cord Blood Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CO Global Cord Blood	N/A	$0.95 flat	N/A	N/A	$115.47M	$1.24B	1.48	1,202
MRAI Marpai	N/A	$0.63 +47.1%	N/A	-54.8%	$16.02M	$34.87M	N/A	150
KMDA Kamada	4.9337 of 5 stars	$8.03 +0.9%	$12.00 +49.5%	+5.8%	$460.60M	$180.46M	22.88	360
KIDS OrthoPediatrics	2.5198 of 5 stars	$17.88 -0.1%	$24.44 +36.7%	-12.2%	$459.25M	$243.30M	N/A	200	Positive News
AUTL Autolus Therapeutics	3.2975 of 5 stars	$1.73 +2.7%	$8.75 +407.2%	-32.3%	$459.10M	$92.62M	N/A	330

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:CO) was last updated on 6/6/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Global Cord Blood (CO) Competitors

CO vs. MRAI, KMDA, KIDS, AUTL, and UPB

How does Global Cord Blood compare to Marpai?

Summary

How does Global Cord Blood compare to Kamada?

Summary

How does Global Cord Blood compare to OrthoPediatrics?

Summary

How does Global Cord Blood compare to Autolus Therapeutics?

Summary

How does Global Cord Blood compare to Upstream Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CO vs. The Competition

Global Cord Blood Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Global Cord Blood (CO) Competitors

CO vs. MRAI, KMDA, KIDS, AUTL, and UPB

How does Global Cord Blood compare to Marpai?

Is CO or MRAI more profitable?

Do insiders & institutionals believe in CO or MRAI?

Which has better valuation & earnings, CO or MRAI?

Which has more volatility and risk, CO or MRAI?

Does the media favor CO or MRAI?

Summary

How does Global Cord Blood compare to Kamada?

Does the media prefer CO or KMDA?

Do analysts rate CO or KMDA?

Which has more volatility & risk, CO or KMDA?

Which has better earnings and valuation, CO or KMDA?

Do institutionals & insiders have more ownership in CO or KMDA?

Is CO or KMDA a better dividend stock?

Is CO or KMDA more profitable?

Summary

How does Global Cord Blood compare to OrthoPediatrics?

Do institutionals and insiders believe in KIDS or CO?

Which has better earnings & valuation, KIDS or CO?

Do analysts prefer KIDS or CO?

Is KIDS or CO more profitable?

Does the media prefer KIDS or CO?

Which has more volatility and risk, KIDS or CO?

Summary

How does Global Cord Blood compare to Autolus Therapeutics?

Does the media favor AUTL or CO?

Do institutionals & insiders have more ownership in AUTL or CO?

Which has preferable earnings & valuation, AUTL or CO?

Which has more volatility & risk, AUTL or CO?

Do analysts prefer AUTL or CO?

Is AUTL or CO more profitable?

Summary

How does Global Cord Blood compare to Upstream Bio?

Which has preferable valuation and earnings, CO or UPB?

Is CO or UPB more profitable?

Do analysts prefer CO or UPB?

Which has more risk and volatility, CO or UPB?

Does the media prefer CO or UPB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CO vs. The Competition

Global Cord Blood Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools